Related by context. All words. (Click for frequent words.) 72 homozygous familial hypercholesterolemia 70 elevated triglyceride levels 69 demonstrated antitumor activity 68 relapsed MM 68 haematologic 68 recurrent glioblastoma multiforme 68 CYT# potent vascular disrupting 67 riociguat 67 BARACLUDE ® 67 nondiabetic patients 66 familial hypercholesterolemia FH 66 evaluating mipomersen 66 AML MDS 66 MAGE A3 ASCI 66 Ribavirin causes 66 nonischemic 66 PLX STROKE targeting 66 eosinophilic asthma 66 HoFH 66 benign prostatic hypertrophy BPH 66 lomitapide 66 Heterozygous Familial Hypercholesterolemia 66 lupus nephritis 66 HIV HCV coinfected 65 smoldering multiple myeloma 65 T1DM 65 thrombocytopenic 65 MKC# MT 65 Aflibercept 65 evaluating tivozanib 65 INCB# [003] 65 autoantibody positive 65 T1c 65 smoldering myeloma 65 β blockers 65 R lenalidomide 65 HeFH 65 induce orthostatic hypotension 65 serum urate levels 65 colorectal adenoma 65 TNF antagonist 65 leukemia AML 65 CTAP# Capsules 65 recurrent VTE 65 AA Amyloidosis 65 psoriatic arthritis PsA 65 galiximab 65 relapsing remitting MS RRMS 65 herpes zoster shingles 65 visilizumab 65 lenalidomide Revlimid R 65 decompensated liver disease 65 LymphoStat B belimumab 65 non alcoholic steatohepatitis 65 pioglitazone HCl 65 locoregional recurrence 65 alvespimycin 65 Cloretazine 65 elevated ALT 65 prolonged QT interval 65 PEGINTRON TM 64 Pioglitazone 64 fluvastatin 64 endometrial hyperplasia 64 memantine Namenda 64 CIMZIA TM certolizumab pegol 64 keloid scarring 64 metastatic HRPC 64 PROSTVAC VF 64 lintuzumab SGN 64 midstage clinical 64 idiopathic PAH 64 retinal vein occlusion induced 64 hyperplasia BPH 64 atherogenic dyslipidemia 64 chronic thromboembolic pulmonary 64 phase III isavuconazole 64 dyslipidaemia 64 NATRECOR R 64 investigational monoclonal antibody 64 anthracycline taxane 64 thrombocytopenic patients 64 refractory gout 64 ximelagatran 64 clomipramine 64 opioid naive 64 trastuzumab Herceptin ® 64 ATACAND 64 Certolizumab pegol 64 unstable angina pectoris 64 Tarceva TM 64 Subgroup analysis 64 SinuNase TM 64 Ophena TM 64 flutamide 64 elacytarabine 64 PAOD 64 systolic dysfunction 64 carotid artery blockage 64 deferiprone 64 proliferative retinopathy 63 grade cervical intraepithelial 63 thromboembolic complications 63 parecoxib 63 underwent resection 63 cytopenias 63 amnestic mild cognitive impairment 63 weekly subcutaneous injections 63 myelodysplastic syndrome MDS 63 rFVIIa 63 including eniluracil ADH 63 OHR/AVR# 63 ZOLINZA 63 erlotinib Tarceva ® 63 hsCRP levels 63 Temsirolimus 63 PSMA ADC 63 ß blockers 63 Erythropoietic therapies may 63 histologically confirmed 63 STRIDE PD 63 sorafenib tablets 63 CIMZIA ™ 63 albiglutide 63 stage IIIb IV 63 intravenous cyclophosphamide 63 Syncria R 63 trial evaluating PRX# 63 sitaxsentan 63 proliferative diabetic retinopathy 63 MGd 63 mRCC 63 Pivotal Phase III 63 Tolvaptan 63 vWD 63 antidepressants fluoxetine 63 elevated LDL cholesterol 63 GSK# [002] 63 recurrent metastatic 63 peritumoral brain edema 63 beta blockers ACE inhibitors 63 hyperphenylalaninemia HPA due 63 liposomal amphotericin B 63 Adjuvant chemotherapy 63 aripiprazole Abilify 63 papillary renal cell carcinoma 63 dose atorvastatin 63 thalidomide Thalomid 63 rituximab refractory 63 candidemia 63 colorectal liver metastases 63 systemic juvenile idiopathic 63 T2DM 63 glycated hemoglobin levels 63 interstitial pneumonitis 63 recombinant PSMA vaccine 63 Telintra 63 DEB# 63 non metastatic osteosarcoma 63 hypercalcemia 63 NYHA Class II 63 neutropenia dehydration dyspnea 63 prostate cancer CaP 63 Fulvestrant 63 minimally symptomatic 63 hematopoietic cancers 63 castrate resistant prostate cancer 63 sorafenib Nexavar 63 hemorrhagic cystitis 63 Zolinza 63 Teriflunomide 63 pediatric malignancies 63 everolimus eluting stents 63 squamous cell lung cancer 63 SPRYCEL ® 63 MS relapses 63 novel VDA molecule 62 silent ischemia 62 severe hypercholesterolemia 62 GOUT 62 potentially hepatotoxic 62 RECORD1 62 adalimumab Humira 62 polyp recurrence 62 diabetic kidney 62 onset diabetes mellitus 62 recurrent glioblastoma 62 Xelox 62 hormone receptor negative 62 severe hypersensitivity reactions 62 kidney urologic 62 phase IIb trial 62 Avandia Actos 62 olmesartan 62 Lipitor #mg 62 invasive candidiasis 62 PREZISTA r 62 metastatic GIST 62 primary hypercholesterolemia 62 medically inoperable 62 relapsed ALL 62 MULTAQ 62 unresectable tumors 62 erythropoietic 62 Myelodysplastic Syndrome MDS 62 either acutely decompensated 62 tumor necrosis 62 Glioblastoma Multiforme 62 tumor lysis syndrome 62 malignant ascites 62 endothelin receptor antagonists 62 ancrod 62 atypical hemolytic uremic syndrome 62 hoFH 62 oral rivaroxaban 62 IV NSCLC 62 myelofibrosis polycythemia vera 62 Enzastaurin 62 antihypertensive therapy 62 pancreatic carcinoma 62 Flu Cy 62 thrombocytopenia neutropenia 62 beta carotene supplementation 62 thrombo embolic 62 neutropenic sepsis 62 6R BH4 62 mildly symptomatic 62 nonmetastatic 62 finasteride Proscar 62 Fibrillex TM 62 postoperative AF 62 systolic hypertension 62 prostate carcinoma 62 antiretroviral naïve 62 Stent thrombosis 62 nucleotide analogue 62 nephrotoxicity 62 oxypurinol 62 beta blocker therapy 62 Atypical Hemolytic Uremic Syndrome 62 underwent liver transplantation 62 curative resection 62 symptomatic BPH 62 LHRH receptor positive 62 macroalbuminuria 62 hormone refractory metastatic prostate 62 ischemic cardiomyopathy 62 treat benign prostatic 62 canakinumab 62 Pivotal Phase 62 invasive aspergillosis 62 recurrent malignant glioma 62 stage IIIB 62 CP CPPS 62 AGILECT R 62 hematologic toxicity 62 steroid refractory GvHD 62 atherothrombotic events 62 Infusion Reactions Severe 62 unstable angina UA 62 serum phosphorous 62 Systemic lupus erythematosus 62 elevated serum creatinine 62 hepatitis C HCV 62 nonalcoholic steatohepatitis 62 pamidronate 62 symptomatic VTE 62 biochemical relapse 62 Hepatotoxicity 62 sertraline Zoloft 62 anthracyclines taxanes 62 receiving XGEVA 62 dapagliflozin plus 62 Hepatocellular Carcinoma HCC 62 Eculizumab 62 Triapine R 62 familial hypercholesterolemia 62 ADPKD 62 paricalcitol 62 Patients Treated With 62 Ramipril 62 metastatic renal 62 precancerous condition 62 elevated fasting glucose 62 IV metastatic melanoma 62 achieved CCyR 62 macrovascular complications 62 HBeAg negative 62 Atherosclerotic 62 cisplatin gemcitabine 62 VADT 62 cardiac repolarization 62 pravastatin therapy 62 colorectal carcinoma 62 monoinfected patients 62 Safinamide 62 hypophosphatemia 62 standard chemotherapy regimen 62 Occlusive Disease 62 2 methoxyestradiol 62 follicular lymphomas 62 Losartan 62 intracerebral haemorrhage 62 Toxicities 62 receptor tyrosine kinase inhibitor 62 hepatocellular carcinomas 62 dosing cohort 62 RhuDex TM 62 steroid refractory 62 occlusive disease 62 chronic GVHD 62 vaso occlusive crisis 62 allogeneic HSCT 62 Gemzar ® 62 HBeAg negative patients 62 schizophrenia CIAS 62 Aliskiren 62 pharmacokinetic interactions 62 VIIBRYD 62 thetreatment 62 heterozygous FH 62 CC genotype 62 darapladib 62 TACI Ig 62 lumiliximab 61 BRIM3 61 nonalcoholic steatohepatitis NASH 61 grade cervical dysplasia 61 nitrofurantoin 61 chronic renal disease 61 retinal vein occlusion 61 elotuzumab 61 Cerebril TM 61 phase IIb clinical 61 Methylnaltrexone 61 orally administered inhibitor 61 metastatic castration resistant 61 neovascular diseases 61 Hypotension 61 hypercalcaemia 61 aortic valve stenosis 61 oxymorphone ER 61 anti arrhythmic drug 61 HER2 positive metastatic breast 61 resistant hormone refractory 61 Asymptomatic 61 myocardial infarction ventricular fibrillation 61 R Saizen R 61 idiopathic thrombocytopenic purpura ITP 61 Pegylated Liposomal Doxorubicin 61 serum phosphate 61 HCV SPRINT 61 aspirin clopidogrel 61 homocysteine concentrations 61 CINQUIL 61 docetaxel prednisone 61 HMG CoA reductase inhibitors 61 Randomized Phase 61 Torsades de Pointes 61 HCV RESPOND 2 61 ventricular tachyarrhythmia 61 advanced adenoma 61 Tacrolimus 61 ORENCIA R 61 #mg ATC 61 GW# [003] 61 heFH 61 biliary tract cancer 61 left ventricular dysfunction 61 phase IIb study 61 oral ridaforolimus 61 metastatic gastric 61 Lupus nephritis 61 prospectively stratified 61 EndoTAG TM -1 61 COPD exacerbation 61 salmeterol HFA MDI 61 fulminant hepatitis 61 heavily pretreated 61 Navelbine ® 61 fasting triglyceride levels 61 REYATAZ r arm 61 XIENCE V demonstrated 61 Genasense ® 61 recurrent atrial fibrillation 61 myopathy rhabdomyolysis 61 tolevamer 61 SJIA 61 estramustine 61 UPLYSO 61 renal insufficiency 61 edifoligide 61 Arranon 61 pT3 61 ACTOS ® 61 atypical Hemolytic Uremic Syndrome 61 asymptomatic metastatic 61 SORT OUT III 61 achieved ACR# 61 oral FTY# 61 INVEGA ® 61 HER2 overexpression 61 morphometric vertebral fractures 61 oral antidiabetic medication 61 #mg dose [002] 61 Relapsing remitting MS 61 Refractory Hodgkin Lymphoma 61 TAXOTERE ® 61 cardiac dysfunction 61 Pegylated Interferon 61 PANVAC VF 61 Bezielle 61 Panzem R 61 pheochromocytoma 61 TORISEL 61 heparin induced thrombocytopenia 61 cervical lymph nodes 61 cerebral vasospasm 61 sulfonylurea metformin 61 myeloproliferative diseases 61 Xanafide 61 metastatic malignant 61 Cleviprex TM clevidipine 61 cutaneous T 61 intermittent claudication 61 antidiabetic drugs 61 bronchodilatory 61 oral prodrug 61 davunetide intranasal AL 61 paclitaxel eluting stents 61 systemic ALCL 61 dexanabinol 61 complement inhibitor eculizumab 61 Renal impairment 61 Celebrex celecoxib 61 perioperatively 61 pentoxifylline 61 eculizumab therapy 61 lactate dehydrogenase LDH 61 rosiglitazone maleate 61 elevated triglycerides 61 drug eluting stent implantation 61 candesartan cilexetil 61 dopaminergic therapy 61 intracranial hemorrhage ICH 61 xanthine oxidase inhibitor 61 Doxil ® 61 transaminase elevations 61 intravascular hemolysis 61 Meets Primary Endpoint 61 fluorouracil leucovorin 61 bisoprolol 61 dacarbazine DTIC 61 hereditary deficiency 61 intravenous RSD# 61 recurrent acute pancreatitis 61 RRMS patients 61 ELACYT 61 BRIM2 61 umol L 61 severe neutropenia 61 YONDELIS 61 exocrine pancreatic insufficiency EPI 61 atrophic gastritis 61 RSD# oral 61 fibrotic disease 61 Phase 2b Clinical Trial 61 anthracycline chemotherapy 61 Golimumab 61 HNSCC 61 acute myelogenous leukemia AML 61 Calcium intake 61 baseline HbA1c 61 chronic myeloid 61 deep venous thromboses 61 oral antidiabetes 61 fasting glucose levels 61 diabetic neuropathic pain 61 venlafaxine Effexor 61 TELINTRA 61 headache nasopharyngitis 61 somatostatin analog 61 Muraglitazar 61 mitoxantrone plus 61 maximally tolerated lipid lowering 61 thiazolidinedione TZD 61 metastatic bladder 61 noncardiovascular 61 paclitaxel cisplatin 61 Cinquil 61 external genital lesions 61 cediranib 61 relapsed refractory multiple myeloma 61 pouchitis 61 PEGylated interferon beta 1a 61 lipid lowering medications 61 enalapril 61 anagrelide 61 cytomegalovirus infection 61 Telithromycin 61 ZACTIMA 61 NOMID 61 relapsed SCLC 61 neutropenic patients 61 unresectable HCC 61 IMA# 61 nonvertebral fracture 61 Paxil paroxetine 61 ALT flares 61 superficial bladder cancer 61 gross hematuria 61 HBeAg 61 mcg BID 61 NNT = 61 secondary hyperparathyroidism 61 azilsartan medoxomil 61 mixed hyperlipidemia 61 mg administered orally 61 ARCALYST ® 61 candidate XP# 61 Non inferiority 61 tramiprosate Alzhemed TM 61 myelodysplastic myeloproliferative diseases 61 PNH patients 60 IL# PE#QQR 60 HIV seropositive 60 Randomized Double blind 60 pancreatic insufficiency 60 NNRTI resistance 60 efaproxiral 60 renal toxicity 60 tumors GIST 60 thrombotic thrombocytopenic purpura TTP 60 oral Hycamtin 60 chronic myocardial ischemia 60 isolated systolic hypertension 60 Tasigna prolongs 60 subclinical hypothyroidism 60 forodesine 60 bovine thrombin 60 Hormone Refractory Prostate Cancer 60 decompensated heart failure 60 Pemetrexed 60 renal cell carcinomas 60 Venous thromboembolism 60 hyperprolactinemia 60 pegylated liposomal doxorubicin 60 EDEMA3 trial 60 renal dysfunction 60 diarrhea predominant irritable 60 catheter occlusion 60 anterior uveitis 60 HIV coinfected 60 tegaserod 60 phenytoin Dilantin 60 VP# [004] 60 metformin accumulation 60 leukemia CLL 60 epithelial tumors 60 citalopram Celexa 60 skeletal metastases 60 Gleevec resistant 60 paroxetine Paxil 60 metastatic hormone refractory 60 Advaxis Phase 60 diabetes mellitus DM 60 moderate renal impairment 60 Cloretazine R 60 comparator arm 60 hematological parameters 60 INS# [001] 60 dirucotide MBP# 60 MGUS 60 budesonide foam 60 CIPN 60 Subgroup analyzes 60 clazosentan 60 cilostazol 60 gemifloxacin 60 FOLFOX6 chemotherapy regimen 60 prednisone prednisolone 60 gouty arthritis 60 treatment naïve genotype 60 TNF blocker therapy 60 anemia neutropenia 60 multivessel disease 60 hepatic failure 60 peripheral arterial occlusive disease 60 Insulin detemir 60 EOquin TM 60 non cirrhotic portal 60 docetaxel Taxotere ® 60 Pooled Analysis 60 Ischemic 60 mycosis fungoides 60 liver transplant recipients 60 hepatorenal syndrome 60 Dementia Related Psychosis 60 severe renal impairment 60 orchitis 60 INSPIRE Trial Phase III 60 intravenous bisphosphonates 60 VICTOR E3 60 SGPT 60 antiarrhythmic drug 60 Non Alcoholic Steatohepatitis 60 aplindore 60 modified REGENESIS Phase IIb 60 Amrubicin 60 quetiapine Seroquel 60 Cariprazine 60 prostate cancer CRPC 60 Aplidin 60 sodium thiosulfate STS 60 lenalidomide dexamethasone 60 temsirolimus 60 nonsmall cell lung cancer 60 bile duct tumors 60 multicenter Phase III 60 evaluable subjects 60 IBS C 60 lipohypertrophy 60 hypercholesterolaemia 60 autoimmune thyroid 60 hyperglycaemia 60 statin monotherapy 60 calcineurin inhibitor 60 postoperative chemotherapy 60 lipid lowering therapy 60 CINTREDEKIN BESUDOTOX 60 immunomodulatory agents 60 Initiated Phase 60 NMIBC 60 QTc prolongation 60 liver decompensation 60 Azacitidine 60 phase IIb III 60 prospectively enrolled 60 overactive bladder syndrome 60 CYP #A# 60 gamma secretase inhibitor 60 visceral metastases 60 treatment naive genotype 60 refractory chronic lymphocytic 60 liver metastasis 60 heterozygous familial hypercholesterolemia 60 mg/m2 dose 60 cisplatin vinorelbine 60 cisplatin chemotherapy 60 Angiotensin receptor blockers 60 recurrent glioma 60 Hp2 2 60 LNG IUS 60 refractory myeloma 60 adriamycin 60 Phase 1b clinical trials 60 Motesanib 60 mild renal insufficiency 60 underwent CABG 60 Phenoptin 60 debilitating complication 60 neutropenia thrombocytopenia 60 recurrent UTI 60 containing abacavir 60 ANAVEX #-# [001] 60 symptomatic hyponatremia 60 unresectable stage 60 haloperidol Haldol 60 ARCOXIA 60 PRIMO CABG 60 radiation sensitizer 60 moderately emetogenic 60 docetaxel Injection Concentrate 60 fibrinolysis 60 intra articular injection 60 metastatic kidney 60 Myelodysplastic Syndrome 60 mucosal healing 60 phase IIa 60 Peripheral arterial disease 60 3TC lamivudine Epivir 60 LV dysfunction 60 bone marrow reticulin deposition 60 PD LID 60 Thrombocytopenia 60 failure NYHA 60 relapsed leukemia 60 Testosterone deficiency 60 interferon gamma 1b 60 Omacetaxine 60 TLK# 60 basal cell nevus syndrome 60 HER2 expression 60 AGHD 60 refractory acute myeloid 60 hyaluronidase enzyme 60 pulmonary hypertension PH 60 FluCAM arm 60 metastatic colorectal 60 hepatic impairment 60 Colon polyps 60 hemorrhagic complications 60 sunitinib malate 60 bezafibrate 60 bortezomib Velcade 60 undergoing CABG 60 mycophenolate mofetil MMF 60 thromboembolic 60 CTEPH 60 Forodesine HCl 60 coinfected patients 60 Myelodysplastic syndromes MDS 60 chronic HBV 60 acyclovir Lauriad R 60 NAGS deficiency 60 pancreatic prostate 60 Malignant glioma 60 hypercholesterolemia 60 myeloproliferative neoplasms 60 Hurthle cell 60 ® lenalidomide 60 AVODART 60 impaired renal 60 metastatic RCC 60 MEVACOR 60 AA amyloidosis 60 INCB# [001] 60 benign prostatic hypertrophy 60 oral hypoglycemic agents 60 RAS blockers 60 CYPHER Stent 60 NATRECOR ® 60 thyrotropin levels 60 pyridostigmine 60 blinded randomized placebo controlled 60 Zollinger Ellison syndrome 60 COREG 60 Prodarsan 60 choroidal neovascularization 60 Cutaneous T 60 mapatumumab 60 LAB CGRP 60 pravastatin Pravachol 60 G6PD deficiency 60 platelet dysfunction 60 Phase IIIb clinical 60 goserelin 60 Bucindolol 60 gestational hypertension 60 carotid endarterectomy CEA 60 unruptured aneurysm 60 Alequel 60 HCV genotype 60 terazosin 60 assessing T DM1 60 teriflunomide 60 patientswith 60 axitinib 60 brain metastases originating 60 Folfox 60 ACTEMRA TM 60 malignant lymphoma 60 chronic HCV infection 60 cranial irradiation 60 recurrent venous thromboembolism 60 etanercept Enbrel 60 abnormal lipids 60 hematological malignancy 60 Severe Primary IGFD 60 placebo controlled clinical 60 hepatic toxicity 60 EGFR mutation positive 60 receiving VELCADE 60 elevated hsCRP 60 heterozygous familial hypercholesterolemia heFH 60 neutropenic fever 60 DAPT 60 ADL# novel 60 macrovascular disease 60 Uterine cancer 60 pyelonephritis 60 R sorafenib tablets 60 Neovascular AMD 60 Sudhir Agrawal D.Phil 60 serum IGF 60 Heavy menstrual bleeding 60 TEAEs 60 antiplatelet agent 60 Chronic pancreatitis 60 Unstable Angina 60 Severe hypoglycemia 60 GH deficiency 60 complete cytogenetic response 60 essential thrombocythemia 60 de novo kidney transplant 60 neovascular 60 EXJADE 60 serum triglycerides 60 5-fluorouracil/leucovorin 60 Postoperative complications 60 hyperlipidemic 60 monoclonal gammopathy 60 Acetaminophen overdose 60 benazepril 60 nondiabetic subjects 60 APTIVUS r 60 recurrent glioblastoma multiforme GBM 60 receptor blocker 60 endometriosis ovarian cysts 60 cIAI 60 sulindac 60 chronic idiopathic thrombocytopenic purpura 59 ischemic colitis 59 hyperlipidaemia 59 acarbose 59 immunodeficient 59 aneurysmal subarachnoid hemorrhage 59 osteosarcomas 59 Cloretazine R VNP#M 59 aldosterone antagonists 59 endothelial activation 59 taxane chemotherapy 59 danazol 59 risperidone Risperdal 59 potassium sparing diuretics 59 metastatic neuroendocrine tumors 59 intensive statin therapy 59 metformin monotherapy 59 PegIFN RBV 59 KRN# 59 Edge STudy 59 prospective multicenter study 59 acute GvHD 59 gastric adenocarcinoma 59 Orally administered 59 antiretroviral naive 59 perioperative complications 59 interstitial pneumonia 59 aplastic anemia AA 59 antiandrogens 59 pretransplant 59 Phase #b/#a clinical 59 hepatitis C genotype 59 Fluvastatin 59 serum uric acid sUA 59 oral vancomycin 59 Patients Receiving 59 Idiopathic Pulmonary Fibrosis IPF 59 Solazed TM 59 baminercept 59 Darusentan 59 efavirenz EFV 59 congenital deficiency 59 Aortic stenosis 59 delayed CINV 59 Cloretazine ® 59 indolent follicular non 59 Adenomas 59 alendronate Fosamax 59 Zarnestra 59 hypertriglyceridemia 59 aflibercept VEGF Trap 59 DCCR 59 corticosteroid therapy 59 arterial thrombotic 59 Saxagliptin 59 DFMO 59 Psoriatic arthritis 59 oropharyngeal candidiasis OPC 59 anthracycline containing 59 posaconazole 59 pT2 59 advanced adenomas 59 genotypic resistance 59 post herpetic 59 glucose intolerant 59 DAS# CRP 59 oral antidiabetic agents 59 renovascular hypertension 59 induced macular edema 59 post herpetic neuralgia PHN 59 Tyrima 59 salmeterol fluticasone 59 symptomatic aortic stenosis 59 obstructive coronary artery 59 cystic fibrosis chronic pancreatitis 59 chorioamnionitis 59 Intervention Effectiveness 59 pseudobulbar affect PBA 59 alefacept 59 Femara letrozole 59 RhuDex ® 59 macrovascular events 59 Zollinger Ellison Syndrome 59 malignant polyps 59 Pegloticase 59 fosbretabulin 59 secondary amenorrhea 59 Aceon 59 tolvaptan 59 alpha interferons 59 acute leukemias 59 BR.# 59 Haptoglobin 59 Hyperlipidemia 59 thyroid deficiency 59 cinacalcet 59 valvular disease 59 DU #b 59 RLAI 59 immune thrombocytopenic purpura 59 metastatic malignant melanoma 59 dyslipidemias 59 radiolabeled TM# 59 recombinant tissue plasminogen 59 mecasermin 59 cetuximab Erbitux 59 inadequate glycemic 59 hypertension diabetes mellitus 59 Velcade bortezomib 59 angiotensin receptor blockers ARBs 59 undergone radical prostatectomy 59 acromegalic patients 59 abnormal glucose tolerance 59 pyrexia mucositis sepsis febrile 59 metastatic renal cell 59 coronary blockages 59 histologic subtype 59 lymphomas leukemias 59 MADIT 59 dysglycemia 59 autonomic dysfunction 59 autologous SCT 59 HGPIN 59 carcinoid syndrome 59 nodal metastasis 59 ischemic complications 59 arterial calcification 59 homozygous FH 59 juvenile idiopathic arthritis JIA 59 CVD mortality 59 generalized seizures 59 Multicenter Randomized 59 Critical Limb Ischemia CLI 59 lupus erythematosus 59 Phase Ib IIa 59 clodronate 59 CLA supplementation 59 LymphoStat B TM 59 pancreatic neuroendocrine tumors 59 KETEK 59 randomized Phase IIb 59 postmenopausal osteoporotic women 59 dalteparin 59 resectable 59 antibiotic rifaximin 59 fatal anaphylactic 59 EVIZON TM squalamine lactate 59 castration resistant prostate cancer 59 multi infarct dementia 59 E selectin 59 Rheumatoid Arthritis RA 59 ginkgo extract 59 MYCN amplification 59 Traficet EN 59 Renal Cell Carcinoma RCC 59 hypervascular tumors 59 immunocompetent 59 IOP lowering 59 hypertension hypercholesterolemia 59 ziprasidone Geodon 59 IgA deficiency 59 anaphylactic reactions bronchospasm 59 metastatic carcinoid 59 abacavir lamivudine 59 octreotide LAR 59 dose escalation phase 59 rhIGF-I/rhIGFBP-3 59 antiphospholipid syndrome 59 desvenlafaxine succinate 59 prokinetic agent 59 Myelofibrosis 59 ABCB1 59 subarachnoid hemorrhage SAH 59 abacavir Ziagen 59 venlafaxine XR 59 primary hyperparathyroidism 59 Phase #b/#a trial 59 ruboxistaurin 59 trastuzumab Herceptin R 59 vasogenic edema 59 antiplatelet medications 59 vasomotor symptoms 59 aminotransferase levels 59 mutated K ras 59 alagebrium 59 narrowed carotid arteries 59 TBC# 59 statistically significant efficacy